核苷类似物处方对乙型肝炎对肝癌在香港的发病率的影响：

StephenW

Effects of nucleoside analogue prescription for hepatitis B on the incidence of liver cancer in Hong Kong: a territory-wide ecological study
Authors

    First published: 15 December 2016
    DOI: 10.1111/apt.13895View/save citation
    Cited by: 0 articles

    Article has an altmetric score of 1
    Funding Information

    The Handling Editor for this article was Professor Geoffrey Dusheiko, and it was accepted for publication after full peer-review.

Summary
Background

The temporal relationship between nucleoside analogue therapy for chronic hepatitis B (CHB) and liver cancer development has not been evaluated at a population level.
Aim

To investigate the impact of nucleoside analogue prescription on liver cancer incidence in a CHB-prevalent region.
Methods

We obtained territory-wide nucleoside analogue prescription data from 1999, when nucleoside analogue was first available in Hong Kong, to 2012 and the population-based liver cancer incidence data from 1990 to 2012. We compared the liver cancer incidences from 1990 to 1998 and 1999 to 2012 with adjustment for local hepatitis B surface antigen seroprevalence.
Results

Nucleoside analogue prescription patient headcount increased from 2006 per year in 1999 to 26 411 in 2012. Prescription volume in 2012 was highest among 55–64 years (30.3%), higher than 65–74 years (13.0%) and ≥75 years (5.8%). Age-standardised liver cancer incidence 1999–2012 decreased by 1.88%/year (95% CI 3.34% to 0.42%/year). NA therapy was associated with decline in age-adjusted liver cancer incidence (2.7 per 100 000 persons, P < 0.001, 95% CI 1.4–4.0 per 100 000 persons). Fifty-five to sixty-four years age group had the most significant decline (men: 24.0 per 100 000 persons, P = 0.001, 95% CI 11.4–36.6 per 100 000 persons; women: 8.5 per 100 000 persons, P = 0.009, 95% CI 2.3–14.6 per 100 000 persons). No significant association was noted in age groups 65–74 years and ≥75 years (both P > 0.05).
Conclusions

Nucleoside analogue prescription was associated with a reduction of overall liver cancer incidence in a CHB-prevalent region. The lack of association among individuals of ≥65 years was consistent with the low nucleoside analogue prescription volume in elderly patients, mitigating the impact of CHB treatment on liver cancer.

StephenW

核苷类似物处方对乙型肝炎对肝癌在香港的发病率的影响：一个领域的生态研究
作者

首次发布：15十二月2016完整的出版历史
DOI：10.1111 / apt.13895查看/保存引文
引用：0文章

文章的得分为1
资金信息

这篇文章的处理编辑是Geoffrey Dusheiko教授，它在完全同行评审后被接受出版。

概要
背景

在核苷类似物治疗慢性乙型肝炎（CHB）和肝癌发展之间的时间关系尚未在人口水平进行评估。
目标

调查核苷类似物处方对CHB流行地区肝癌发病率的影响。
方法

我们从1999年（当时首次在香港提供核苷类似物，到2012年）和从1990年到2012年的基于人群的肝癌发病率数据获得了全境核苷类似物处方数据。我们比较了1990年到1998年和1999年的肝癌发病率2012年调整局部乙型肝炎表面抗原血清阳性率。
结果

核苷类似物处方患者人数从1999年的2006年增加到2012年的26 411. 2012年处方量在55-64岁（30.3％），高于65-74岁（13.0％）和≥75岁（5.8岁） ％）。 1999 - 2012年的年龄标准化肝癌发病率下降了1.88％/年（95％CI 3.34％至0.42％/年）。 NA治疗与年龄校正的肝癌发病率下降相关（2.7 / 10万人，P <0.001，95％CI 1.4-4.0 / 10万人）。五十五至六十四岁组有最显着的下降（男性：24.0 / 10万人，P = 0.001,95％CI 11.4-P = 0.009,95％CI 2.3-14.6每10万人）。在65-74岁和≥75岁的年龄组没有显着关联（P> 0.05）。
结论

核苷类似物处方与CHB-普遍区域中总体肝癌发生率的降低相关。 ≥65岁的个体之间缺乏关联与老年患者的低核苷类似物处方体积一致，减轻了CHB治疗对肝癌的影响。

baobao7676

很好啊，说明核苷能把肝癌发生概率降低到原来的1/2~1/3